Study of an investigational pentavalent meningococcal ABCYW vaccine against meningococcal disease in adults and adolescents
The rise in infectious disease outbreaks in recent decades
underscores the need to find better and safer vaccines to protect individuals and the public.
To answer the need for a vaccine providing protection against
the 5 most epidemiologically relevant N. meningitidis serogroups worldwide (A, B, C, W, and Y) and to reduce the need for multiple injections with multiple vaccines, Sanofi is developing a new pentavalent meningococcal ABCYW vaccine, referred to hereafter as MenPenta.
The purpose of this Phase I/II study is to assess the safety and
immunogenicity of 2 formulations of MenPenta relative to the
safety and immunogenicity of the licensed comparator vaccines.
Please fill out the form below to get in contact with MediSphere if you'd like to be part of our current medical studies.
Address
Hours
Mon-Fri: 7:30am - 5:00pm
Sat-Sun: CLOSED